Blebbistatin, Racemic

A cell-permeable compound that acts as a selective, potent, and reversible inhibitor of non-muscle myosin II. Inhibits the ATPase and gliding motility of human platelets (≤100 µM) without affecting myosin light chain kinase (MLCK) activity. Has been shown to block cell blebbing and to rapidly disrupt directed cell migration and cytokinesis in vertebrate cells. Does not disrupt mitosis or affect contractile ring assembly.

Cell permeable: yes

Primary Target
ATPase

Product does not compete with ATP.

Reversible: yes

Target IC₅₀: <100 µM inhibiting the ATPase and gliding motility of human platelets

Packaged under inert gas

A 50 mM (5 mg/342 µl) solution of (±)-Blebbistatin (Cat. No. 203390 ) in 90% DMSO.

Following initial thaw, aliquot and freeze (-20°C).

Shu, S., et al. 2005. Proc. Natl. Acad. Sci. USA102, 1472.
Kovacs, M., et al. 2004. J. Biol. Chem.279, 35557.
Straight, A.F., et al. 2003. Science299, 1743.
Cheung, A., et al. 2001. Mol. Biol. Cell Suppl.12, 271a.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Harmful & Carcinogenic / Teratogenic (E)